Skip to main content

Table 1 Clinicopathological factors according to time of recurrence

From: Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence

    

p Values

 

Early recurrence (n = 184)

Late recurrence (n = 134)

No recurrence (n = 321)

Early vs no recurrence

Late vs no recurrence

Early vs late recurrence

Age, years

      

  ≤ 50

82 (44.57)

49 (36.57)

120 (37.38)

0.113

0.869

0.151

  > 50

102 (55.43)

85 (63.43)

201 (62.62)

   

Menopausal status

      

 Postmenopausal

90 (48.91)

81 (60.45)

171 (53.27)

0.345

0.159

0.041

 Premenopausal

94 (51.09)

53 (39.55)

150 (46.73)

   

Bilateral breast cancer

      

 Absent

169 (91.85)

121 (90.30)

319 (99.38)

<0.001

<0.001

0.631

 Present

15 (8.15)

13 (9.70)

2 (0.62)

   

Tumor size, mm

      

  ≤ 20

49 (26.63)

44 (32.84)

187 (58.26)

<0.001

<0.001

0.23

  > 20

135 (73.37)

90 (67.16)

134 (41.74)

   

Nodal metastasis

      

 Negative

93 (50.54)

79 (58.96)

267 (83.18)

<0.001

<0.001

0.136

 Positive

91 (49.46)

55 (41.04)

54 (16.82)

   

Histological type

      

 IDC-NST

171 (92.93)

124 (92.54)

297 (92.52)

0.864

0.995

0.892

 Others

13 (7.07)

10 (7.46)

24 (7.48)

   

Estrogen receptor staining

      

  < 10 %

16 (8.70)

10 (7.46)

27 (8.41)

0.396

0.367

0.915

 10–50 %

57 (30.98)

43 (32.09)

82 (25.55)

   

  ≥ 50 %

111 (60.33)

81 (60.45)

212 (66.04)

   

Progesterone receptor staining

      

  ≤ 20 %

85 (46.20)

59 (44.03)

133 (41.43)

0.298

0.609

0.701

  > 20 %

99 (53.80)

75 (55.97)

188 (58.57)

   

Tumor grade

      

 1 or 2

131 (71.20)

106 (79.10)

278 (86.60)

<0.001

0.049

0.107

 3

53 (28.80)

28 (20.90)

43 (13.40)

   

Ki-67 staining

      

  ≤ 20 %

136 (73.91)

114 (85.07)

265 82.55)

0.022

0.507

0.014

  > 20 %

48 (26.09)

20 (14.93)

56 (17.45)

   

Local recurrence

      

 Absent

136 (78.61)

96 (71.64)

0

   

 Present

37 (21.39)

38 (28.36)

0

   

Surgical treatment

      

 Total mastectomy

117 (63.59)

78 (58.21)

106 (33.02)

0.076

<0.001

0.331

 Partial mastectomy

67 (36.41)

56 (41.79)

215 (66.98)

   

Radiation therapy

      

 Absent

100 (54.35)

92 (68.66)

149 (46.42)

<0.001

<0.001

0.009

 Present

84 (45.65)

42 (31.34)

172 (53.58)

   

Adjuvant treatment

      

 None

13 (7.07)

4 (2.99)

30 (9.35)

<0.001

<0.001

0.021

 Chemotherapy only

19 (10.33)

6 (4.48)

7 (2.18)

   

 Endocrine therapy only

53 (28.80)

55 (41.04)

180 (56.07)

   

 Combined therapy

99 (53.80)

69 (51.49)

104 (32.40)

   

Neoadjuvant chemotherapy

      

 Absent

168 (91.30)

131 (97.76)

305 (95.31)

0.076

0.198

0.011

 Present

16 (8.70)

3 (2.24)

15 (4.69)

   

Chemotherapy

      

 A + T

54 (29.35)

22 (16.42)

42 (13.08)

   

 A

39 (21.20)

31 (23.13)

40 (12.46)

   

 T

6 (3.26)

7 (5.22)

13 (4.05)

   

 CMF

17 (9.24)

12 (8.96)

13 (4.05)

   

 Other

2 (1.09)

3 (2.24)

3 (0.93)

   

 None

66 (35.87)

59 (44.03)

210 (65.42)

   

Endocrine therapy

      

 TAM

61 (33.15)

34 (25.37)

68 (21.18)

   

 TAM + LHRH

30 (16.30)

18 (13.43)

35 (10.90)

   

 TAM → AI

16 (8.70)

36 (26.87)

72 (22.43)

   

 TAM + LHRH → AI

1 (0.54)

3 (2.24)

15 (4.67)

   

 AI

39 (21.20)

27 (20.15)

87 (27.10)

   

 LHRH

5 (2.72)

6 (4.48)

7 (2.18)

   

 None

32 (17.39)

10 (7.46)

37 (11.53)

  
  1. Abbreviations: IDC-NST invasive ductal carcinoma of no special type, A + T anthracycline and taxane, A anthracycline, T taxane, CMF cyclophosphamide, methotrexate, and fluorouracil, TAM tamoxifen, TAM + LHRH tamoxifen and luteinizing hormone-releasing hormone, TAM → AI tamoxifen followed by aromatase inhibitor, TAM + LHRH → AI tamoxifen and luteinizing hormone-releasing hormone followed by aromatase inhibitor, AI aromatase inhibitor, LHRH luteinizing hormone-releasing hormone
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us